These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32970704)

  • 1. Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models.
    Pinto N; Prokopec SD; Ghasemi F; Meens J; Ruicci KM; Khan IM; Mundi N; Patel K; Han MW; Yoo J; Fung K; MacNeil D; Mymryk JS; Datti A; Barrett JW; Boutros PC; Ailles L; Nichols AC
    PLoS One; 2020; 15(9):e0239315. PubMed ID: 32970704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9.
    Schmerwitz UK; Sass G; Khandoga AG; Joore J; Mayer BA; Berberich N; Totzke F; Krombach F; Tiegs G; Zahler S; Vollmar AM; Fürst R
    Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):280-8. PubMed ID: 21088252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
    Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin Inhibits Cell Proliferation and Migration in Human Anaplastic Thyroid Cancer.
    Chen MC; Tsai YC; Tseng JH; Liou JJ; Horng S; Wen HC; Fan YC; Zhong WB; Hsu SP
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29236027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
    Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
    Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
    Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
    Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3β/ANG Signaling Pathway in Anaplastic Thyroid Cancer.
    Jin Z; Cheng X; Feng H; Kuang J; Yang W; Peng C; Shen B; Qiu W
    Cell Physiol Biochem; 2017; 44(4):1471-1484. PubMed ID: 29190616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flavonoid Fraction of Citrus reticulata Juice Reduces Proliferation and Migration of Anaplastic Thyroid Carcinoma Cells.
    Celano M; Maggisano V; De Rose RF; Bulotta S; Maiuolo J; Navarra M; Russo D
    Nutr Cancer; 2015; 67(7):1183-90. PubMed ID: 26365817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ophiopogonin D' inhibited tumour growth and metastasis of anaplastic thyroid cancer by modulating JUN/RGS4 signalling.
    Xu T; Zhang W; Zhang Y; Song F; Huang P
    J Cell Mol Med; 2024 Aug; 28(16):e70014. PubMed ID: 39153211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
    Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
    Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
    Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
    Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
    Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
    Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.
    Weinlander E; Somnay Y; Harrison AD; Wang C; Cheng YQ; Jaskula-Sztul R; Yu XM; Chen H
    J Surg Res; 2014 Jul; 190(1):191-7. PubMed ID: 24679699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy.
    Mi L; Liu J; Zhang Y; Su A; Tang M; Xing Z; He T; Wei T; Li Z; Wu W
    Phytomedicine; 2024 Jul; 129():155670. PubMed ID: 38704915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle.
    Turkmen E; Sogutlu F; Erdogan M; Biray Avci C
    Med Oncol; 2023 Jun; 40(7):196. PubMed ID: 37284891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.
    Pinto N; Prokopec SD; Vizeacoumar F; Searle K; Lowerison M; Ruicci KM; Yoo J; Fung K; MacNeil D; Lacefield JC; Leong HS; Mymryk JS; Barrett JW; Datti A; Boutros PC; Nichols AC
    PLoS One; 2018; 13(11):e0207152. PubMed ID: 30419054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
    Zhu X; Park S; Lee WK; Cheng SY
    Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
    Wang W; Zhou J; Zhao L; Chen S
    Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.